BacteriologyPrevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa
Introduction
Pseudomonas aeruginosa is an important pathogen associated with serious nosocomial infections. In 2003, P. aeruginosa was reported to be the most commonly isolated Gram-negative bacteria (18.1%) for nosocomial pneumonia and the second most commonly isolated Gram-negative bacteria (16.3%) for nosocomial urinary tract infection in the United States (Gaynes and Edwards, 2005). Treatment of infections due to P. aeruginosa can be difficult; bloodstream infections due to P. aeruginosa are especially detrimental and associated with mortality rates that range from 18% to 62% (Vidal et al., 1996).
Carbapenems are traditionally one of the last lines of agents that are used for difficult-to-manage pseudomonal infections. Carbapenem resistance in P. aeruginosa was reported to increase steadily over the years across the United States (Livermore, 2002, Gaynes and Edwards, 2005), but the relative contribution of different carbapenem resistance mechanisms is not well established. Consequently, the primary objective of the study was to determine the prevalence and mechanisms of carbapenem resistance in bloodstream isolates obtained from our institution. A secondary objective of the study was to identify risk factors associated with carbapenem resistance. It is anticipated that an improved understanding of the prevalence, mechanism, and risk factors of carbapenem resistance in P. aeruginosa may guide formulary decisions and the choice of empiric therapy for nosocomial infections in hospitals.
Section snippets
Study site
St. Luke's Episcopal Hospital is an 800-bed university-affiliated teaching hospital in Houston, TX. There are more than 120 intensive care unit beds in the hospital, and more than 100 open-heart surgeries are performed each month. This study was approved by the institutional review board of the hospital and the University of Houston, Houston, TX.
Bacteria and resistance screening
All nonrepeat (>7 days apart) bloodstream isolates of P. aeruginosa from 2003 and 2004 and their susceptibilities were obtained from the clinical
Bacteria, resistance screening, and genotyping
A total of 129 nonrepeat P. aeruginosa isolates were available, of which 21 (from 18 unique patients) were resistant to meropenem or imipenem (prevalence rate = 16.3%). All patients were hospitalized at least 48 h, and cross-resistance between meropenem and imipenem was found in 19 of 21 isolates. (Twenty isolates were resistant to meropenem and 20 isolates were resistant to imipenem.) In addition, cross-resistance to other antimicrobial agents was common: piperacillin/tazobactam (57%),
Discussion
P. aeruginosa is one of the most common pathogens implicated in serious nosocomial infections such as pneumonia and sepsis. Resistance to the commonly used agents has become more prevalent (Gales et al., 2002). If the rapid spread of antimicrobial resistance is unchecked, the serious threat to turn our era back to the preantibiotic age exists, wiping out the quantum leaps achieved a generation ago in the control of infectious diseases (Landman et al., 2002). Clearly, understanding the
Acknowledgments
The authors thank Stacie Frye, Ph.D. (Bacterial Barcodes) for technical assistance in interpreting the genotyping results. This study was supported in part by the Infectious Diseases Practice and Research Network, American College of Clinical Pharmacy Research Institute (Lenexa, KS) minisabbatical to V.H.T. K.P. is supported by the Canadian Cystic Fibrosis Foundation.
References (24)
- et al.
Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997–2000)
Diagn. Microbiol. Infect. Dis.
(2002) - et al.
Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa
Diagn. Microbiol. Infect. Dis.
(2005) - et al.
Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa
Clin. Microbiol. Infect.
(2007) - et al.
Characterization of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM-1 metallo-beta-lactamase in a hospital located in Rio de Janeiro, Brazil
Microb. Drug. Resist.
(2006) Performance Standards for Antimicrobial Testing: Seventeenth Informational Supplement. CLSI Document M100-S17
(2007)- et al.
Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates
APMIS
(2005) - et al.
Overview of nosocomial infections caused by gram-negative bacilli
Clin. Infect. Dis.
(2005) - et al.
Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned
Arch. Intern. Med.
(2002) - et al.
Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate
Antimicrob. Agents Chemother.
(1999) Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?
Clin. Infect. Dis.
(2002)
First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States
Antimicrob. Agents Chemother.
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy
Antimicrob. Agents Chemother.
Cited by (42)
The impact of carbapenem-resistant Pseudomonas aeruginosa on clinical and economic outcomes in a Chinese tertiary care hospital: A propensity score–matched analysis
2019, American Journal of Infection ControlRisk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems
2017, Journal of Microbiology, Immunology and InfectionCitation Excerpt :Among the 18 deceased patients, nine (50%) received carbapenems as initial empirical antibiotic treatment, but none of the survivors received carbapenems as initial empirical antibiotic treatment (p = 0.027; Table 3). Risk factors of developing carbapenem-resistant P. aeruginosa are comorbidities, length of hospital stay, mechanical ventilation, arterial catheter insertion, prolonged neutropenia, and broad-spectrum antipseudomonal antibiotic use.6,9,15–17 Most of the carbapenem-resistant P. aeruginosa blood isolates in previous studies had cross-resistance to other antipseudomonal antibiotics.3,6,7
Stemming the tide?: Advances in antibiotic discovery and development in the face of emerging resistance and financial constraint
2012, Current Opinion in PharmacologyA model to predict mortality following Pseudomonas aeruginosa bacteremia
2012, Diagnostic Microbiology and Infectious DiseaseCitation Excerpt :All statistical analyses were performed using SYSTAT® version 12.0 (Systat Software, Chicago, IL, USA). The clonality of the MDR strains was assessed by repetitive element–based polymerase chain reaction, as described previously (Tam et al., 2007, 2010a). A total of 114 patients with P. aeruginosa bacteremia were identified from 2007-2008 and 49 patients were identified in 2009.
This study was presented in part at the Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract C2-411), San Francisco, CA, September 27–30, 2006.